Icahn Partners LP v. Francis deSouza

Court of Chancery of Delaware·Decided January 16, 2024·No. C.A. No. 2023-1045-PAF·Published

Opinion

COURT OF CHANCERY

OF THE

STATE OF DELAWARE

PAUL A. FIORAVANTI, JR. LEONARD L. WILLIAMS JUSTICE CENTER VICE CHANCELLOR 500 N. KING STREET, SUITE 11400 WILMINGTON, DELAWARE 19801-3734

Date Submitted: November 9, 2023 Date Decided: January 16, 2024

C. Barr Flinn, Esquire A. Thompson Bayliss, Esquire M. Paige Valeski, Esquire Eric A. Veres, Esquire Young Conaway Stargatt Michael T. Manuel, Esquire & Taylor, LLP Abrams & Bayliss LLP 1000 North King Street 20 Montchanin Road, Suite 200 Wilmington, DE 19801 Wilmington, DE 19807

Peter J. Walsh, Jr., Esquire Michael A. Pittenger, Esquire Justin T. Hymes, Esquire Potter Anderson & Corroon LLP 1313 North Market Street, 6th Floor Wilmington, DE 19801

RE: Icahn Partners LP et al. v. Francis deSouza et al., C.A. No. 2023-1045-PAF

Dear Counsel:

This letter opinion resolves the motion to strike portions of the complaint.

Defendants seek to strike the allegations that were derived from privileged or confidential board-level communications and delivered to the Plaintiffs by a director of Nominal Defendant Illumina, Inc. (“Illumina” or the “Company”). For the reasons discussed herein, the motion is granted.

C.A. No. 2023-1045-PAF January 16, 2024 Page 2 of 33

I. BACKGROUND1 Illumina is a life sciences company that develops tools and systems for genetic analysis.2 In 2015, it formed a subsidiary named GRAIL, Inc. (“GRAIL”) to develop a blood-based cancer-detection test utilizing Illumina’s main-line DNA sequencing technology. 3 Illumina chose to reduce its ownership stake in GRAIL to less than 20% in a February 2017 spin-off, stating publicly that doing so would encourage investment in GRAIL and comparable technologies.4 Over the next three years, GRAIL raised $1.9 billion dollars through private financing options and went public on September 9, 2020. 5 On September 20, 2020, 11 days after GRAIL’s initial public offering, Illumina announced that it had agreed to reacquire its former subsidiary for $8 billion.6

1 The recitation of facts is drawn from the verified complaint, the documents integral thereto, the briefing on this motion, and information subject to judicial notice. The court has taken care to avoid disclosure of the specific information that is the subject of this motion. Citations to the docket in this action are in the form of “Dkt. [#].” In citations, the complaint in this action, Dkt. 1, will be cited as “Compl.” After being identified initially, individuals are referenced herein by their surnames without regard to formal titles such as “Dr.” No disrespect is intended. 2 Compl. ¶ 35.

3 Id. ¶¶ 35–36.

4 Id. ¶ 38.

5 Id. ¶ 39.

6 Id. ¶ 40.

C.A. No. 2023-1045-PAF January 16, 2024 Page 3 of 33

The proposed merger drew scrutiny from regulators in the United States and the European Union. 7 On March 30, 2021, the United States Federal Trade Commission (the “FTC”) filed an administrative complaint seeking to block the merger and authorized a federal suit to obtain an injunction to prevent the deal from closing prior to the resolution of the administrative trial.8 The European Union’s European Commission (“EC”) formally initiated its own investigation on April 19, 2021, triggering an automatic standstill under the EU Merger Regulation.9 The FTC dismissed its federal complaint seeking injunctive relief without prejudice to its ability to renew its claim if the standstill under EU regulations were lifted but maintained the administrative proceeding. 10 Notwithstanding the standstill and pending regulatory review in the US and EU, Illumina closed the acquisition on August 18, 2021. 11 In response, the EC ordered Illumina to keep the companies separate and not to share confidential information, but required Illumina to fully fund GRAIL while the EC’s review was ongoing. 12 On September 6, 2022, the EC issued

7 Id. ¶ 42.

8 Id. ¶¶ 42–43.

9 Id.

10 Id. ¶ 43.

11 Id. ¶ 63.

12 Id. ¶ 67.

C.A. No. 2023-1045-PAF January 16, 2024 Page 4 of 33

a final ruling prohibiting Illumina from acquiring GRAIL and ordered Illumina to divest GRAIL.13 On March 31, 2023, the FTC also ordered Illumina to divest GRAIL. 14 On July 12, 2023, the EC levied a €432 million fine (equivalent to $476 million at the time of the complaint) against Illumina for violating the standstill.15 On February 13, 2023, Plaintiffs Icahn Partners LP, Icahn Partners Master Fund LP, and Matsumura Fishworks LLC became stockholders of Illumina.16 All three Plaintiffs are controlled by Carl Icahn.17 On April 27, 2023, the Plaintiffs, which collectively owned approximately 1.4% of Illumina’s outstanding common stock, 18 proposed a three-candidate slate to challenge the Company’s nominees at the 2023 annual meeting of stockholders.19 One of the Plaintiffs’ nominees, Andrew

13 Id. ¶¶ 68–69.

14 Id. ¶ 70.

15 See id. ¶ 6; Illumina, Inc., Quarterly Report (Form 10-Q) (Nov. 13, 2023) at 26. “The court may take judicial notice of facts publicly available in filings with the SEC.” Omnicare, Inc. v. NCS Healthcare, Inc., 809 A.2d 1163, 1167 n.3 (Del. Ch. 2002) (citing In re Santa Fe Pac. Corp. S’holder Litig., 669 A.2d 59, 69–70 (Del. 1995)); accord In re Gen. Motors (Hughes) S’holder Litig., 897 A.2d 162, 169 (Del. 2006) (“The trial court may also take judicial notice of matters that are not subject to reasonable dispute.”). 16 Illumina’s Opening Br. 4.

17 Id. at 6–7.

18 Id. Ex. B at 2; Compl. ¶ 14.

19 Illumina’s Opening Br. 6.

C.A. No. 2023-1045-PAF January 16, 2024 Page 5 of 33

Teno, is an employee of Icahn Capital LP, which is also controlled by Icahn.20 At the May 25, 2023, annual meeting, Illumina’s stockholders elected Teno to the Company’s Board of Directors (the “Board”). 21 Plaintiffs’ other two nominees were not elected.22 About one week before the election, the Plaintiffs delivered a demand to inspect books and records under 8 Del. C. § 220 to Illumina, requesting information about the GRAIL transaction, among other matters. 23 On May 18, 2023, the Company agreed to produce certain non-privileged documents, conditioned upon the demanding stockholders’ entering into a confidentiality agreement.24 The Plaintiffs have not responded to the Company’s offer. 25 In connection with his joining the Board, Teno agreed to abide by the Company’s Code of Conduct, which provides, among other things, that, “[e]xcept as required for the proper performance of your duties, you may not use or give to

20 Id. at 6–7.

21 Id. at 7.

22 Id.

23 Id.; id. Ex. D.

24 Id. at 7.

25 Id.

C.A. No. 2023-1045-PAF January 16, 2024 Page 6 of 33

others trade secrets or confidential information of the Company.” 26 After being seated on the Board, Teno received privileged and confidential Company information, including information that predated his tenure on the Board.27 Teno subsequently provided privileged and confidential information to Icahn and his affiliates. 28 Using this information, Plaintiffs drafted their complaint in this action, bringing direct and derivative claims alleging that Francis deSouza, John W. Thompson, Frances Arnold, Caroline Dorsa, Robert Epstein, Scott Gottlieb, Gary Guthart, Philip Schiller, and Susan Siegel (the “Individual Defendants”) breached their fiduciary duties.29 Plaintiffs filed their complaint on October 17, 2023, as a confidential filing under Court of Chancery Rule 5.1. 30 It is undisputed that the complaint contains information from Illumina that is protected by the attorney-client privilege. 31

26 Pls.’ Opp’n Br. 32 (internal quotation marks omitted).

27 Illumina’s Opening Br. 8.

28 Id.; Pls.’ Opp’n Br. 5.

29 Illumina’s Opening Br. 9; Compl. ¶¶ 109–28. Shortly after the filing of Plaintiffs’ complaint, two other stockholder groups entered appearances in this action and informed the court that they have served demands upon the Company to inspect books and records relating to the same claims asserted in this action. See Dkts. 17–18, 20–21. As of the publishing of this letter ruling, neither stockholder group has filed a plenary complaint. 30 Dkt. 1.

Free access — add to your briefcase to read the full text and ask questions with AI

Icahn Partners LP v. Francis deSouza, (Del. Ct. App. 2024).

Icahn Partners LP v. Francis deSouza (Icahn Partners LP v. Francis deSouza) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

In Re Teleglobe Communications Corp.
493 F.3d 345 (Third Circuit, 2007)
Henshaw v. American Cement Corporation
252 A.2d 125 (Court of Chancery of Delaware, 1969)
Omnicare, Inc. v. NCS Healthcare, Inc.
809 A.2d 1163 (Court of Chancery of Delaware, 2002)
In Re General Motors (Hughes) Shareholder Litigation
897 A.2d 162 (Supreme Court of Delaware, 2006)
In Re Santa Fe Pacific Corp. Shareholder Litigation
669 A.2d 59 (Supreme Court of Delaware, 1995)
Schoon v. Smith
953 A.2d 196 (Supreme Court of Delaware, 2008)
Kortüm v. Webasto Sunroofs, Inc.
769 A.2d 113 (Court of Chancery of Delaware, 2000)
Appriva Shareholder Litigation Co. v. Ev3, Inc.
937 A.2d 1275 (Supreme Court of Delaware, 2007)
Brophy v. Cities Service Co.
70 A.2d 5 (Court of Chancery of Delaware, 1949)
KLM Royal Dutch Airlines v. Checchi
698 A.2d 380 (Court of Chancery of Delaware, 1997)
Crumplar v. Superior Court ex rel. New Castle County
56 A.3d 1000 (Supreme Court of Delaware, 2012)
In re Information Management Services, Inc. Derivative Litigation
81 A.3d 278 (Court of Chancery of Delaware, 2013)
Garner v. Wolfinbarger
430 F.2d 1093 (Fifth Circuit, 1970)